CME Presentations

Immunotherapy Best Practices: Overcoming Clinical Challenges and Enhancing Treatment in Solid Tumors


Presentations


Speakers

  • Roy Herbst, MD, PhD

    Roy Herbst, MD, PhD

    Roy Herbst, MD, PhD

    Ensign Professor of Medicine (Oncology)

    Roy S. Herbst, MD, PhD, is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut. Dr Herbst has led phase I development of several new-generation targeted agents for non-small cell lung cancer (NSCLC). His laboratory work, which focuses on immunotherapy angiogenesis, EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways, has been translated from preclinical to clinical settings in multiple Phase II and III studies. He has authored or co-authored more than 300 publications, including peer-reviewed journal articles, abstracts, and book chapters.
  • Ignacio Wistuba, MD

    Ignacio Wistuba, MD

    Ignacio Wistuba, MD

    Professor and Chair, Department of Translational Molecular Pathology

    Ignacio I. Wistuba, MD, is division head ad interim of the Division of Pathology and Laboratory Medicine, and professor and chair of the Department of Translational Molecular Pathology at M.D. Anderson Cancer Center in Houston, Texas. His research involves the elucidation of molecular abnormalities in the pathogenesis and progression of lung cancer, and the identification of novel molecular targets and validation of biomarkers for therapies of solid tumors, which has resulted in over 600 peer-reviewed papers. Dr Wistuba currently serves as the pathologist of the Lung Cancer Mutation Consortium (LCMC), a member of the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC), and senior editor of Cancer Prevention Research (AACR) and Annals of Oncology (ESMO).

CME Information

Refining Patient Selection for Biomarker-Directed Immunotherapy


PIM LogoPQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Examine the variety of biomarkers associated with immune checkpoint inhibitor therapy
  • Select appropriate, evidence-based testing modalities for patients who are potential candidates for immune checkpoint inhibitor therapy and interpret testing results effectively
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC in collaboration with the Society for Immunotherapy of Cancer.

ACKNOWLEDGEMENT

This activity is supported by educational grants from Bristol-Myers Squibb Company, Celgene Corporation, Genentech, and Tesaro, A GSK Company.

TUITION

Complimentary

JointlyAccreditedProvider Logo

CREDIT DESIGNATION STATEMENTS

Live Activity

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

June 10, 2020
• 12:00pm – 1:00pm ET: Refining Patient Selection for Biomarker-Directed Immunotherapy

Enduring Material

The enduring material will be available from June 10, 2020 – February 28, 2021.

TARGET AUDIENCE

Medical, surgical, and radiation oncologists; primary care physicians; internal medicine specialists; health care professionals including oncology pharmacists, oncology advanced practice nurses and physician assistants, and other health care providers who participate in the care of patients with cancer.

ESTIMATED TIME TO COMPLETE

This activity consists of one session which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test..

HARDWARE / SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Roy S. Herbst, MD, PhD Consulting Fees: Abbvie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serrano, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Midas Health Analytics, Mirati Theraputics, Nektar, Neon Theraputics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen
Contracted Research: AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company
Other: Junshi Pharmaceuticals
Ignacio I. Wistuba, MD Consulting Fees: AstraZeneca/Medimmune, Asuragen, Bayer, Bristol-Myers Squibb, Guardant Health, Genentech/Roche, GlaxoSmithKline, HTG Molecular, Merck, MSD, Pfizer
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Genentech/Roche, MSD, Pfizer
Contracted Research: Adaptive, Adaptimmune, Akoya, Amgen, Bayer, Bristol-Myers Squibb, DepArray, EMD Sorono, Genentech, HTG Molecular, Iovance, Johnson & Johnson, Karus, Medimmune, Merck, Novartis, Oncocyte, Oncoplex, Pfizer, Takeda, 4D

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.